Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Astellas Vows Intensive Investment in 6 Late-Stage Assets to Weather Patent Cliff: CEO
Astellas Pharma President and CEO Kenji Yasukawa on April 26 highlighted the company’s resolve to plow intensive resources into six late-stage pipelines, including the cancer drug candidate IMAB362 (zolbetuximab), in a bid to tackle a looming patent cliff for its…
To read the full story
Related Article
- Astellas Eyes 1 Trillion Yen Peak Sales with 6 Late-Stage Assets: Biz Plan
May 23, 2018
- Astellas Sales Drop 0.9% due to LLP Sell-Off, Japan Biz Hit by Generic Entry
April 27, 2018
- Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
BUSINESS
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Astellas Kicks Off Global PIII of KRAS G12D Degrader Setidegrasib
April 16, 2026
- G1 Reform Will Accelerate LLP Transfers, Fuel Competition: LTL Chief
April 15, 2026
- Daiichi Sankyo’s I-DXd Filed in US for SCLC, Wins Priority Review
April 15, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…